JFL(SH:600901) Mei Ri Jing Ji Xin Wen·2025-10-24 13:52Group 1: Company Performance - Jiangsu Jinzu reported a revenue of approximately 4.638 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 17.15% [1] - The net profit attributable to shareholders was about 2.446 billion yuan, showing a year-on-year increase of 9.82% [1] - Basic earnings per share decreased by 17.65% to 0.42 yuan [1] Group 2: Market Context - As of the report date, Jiangsu Jinzu's market capitalization stood at 34.8 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales totaling 80 billion dollars this year [2] - The secondary market for biopharmaceuticals is experiencing a surge, while the primary market is facing challenges in fundraising [2]